Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Continues Restructuring: Lays Off 30, Brings on New CBO, Board Member

NEW YORK, April 28 - In the latest phase of a restructuring plan that began in July 2002, Aclara today said it has let go an additional 30 employees, hired a new chief business officer, and appointed a new member to its board of directors.

 

Aclara said it carried out these steps with the goal of further increasing its focus on commercializing its eTag assay system - a strategy the company began implementing in July, when it first announced its restructuring plans and the elimination of 50 staffers.

 

Today, Aclara said it would eliminate an additional 30 positions in executive management, administration, marketing, and basic research, bringing its total headcount to 65.

 

"We believe these actions, while certainly difficult, allow us to focus on our most important priority, the commercialization and rapid adoption of eTag assays," said Thomas Klopack, Aclara's CEO, in a statement.

 

Michael Dunn, formerly executive VP of business development at Aurora Biosciences, will join the company to fill the new position of CBO, where he will be responsible for business development, sales, and marketing.

 

In addition, Affinium Pharmaceuticals CEO John Mendlein has been appointed to Aclara's board of directors.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more